Jennifer N Durham

17PUBLICATIONS
160CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersRegenerative medicine (incl. stem cells)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Jan 12, 2026
Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses.

Dimitrios N Sidiropoulos, Zhehao Zhang, Jennifer N Durham

|Jan 12, 2026
A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC.

Katherine M Bever, Amanda L Huff, Ludmila Danilova

|Sep 15, 2025
Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy.

Howard L Li, Soren Charmsaz, Mari Nakazawa

|May 19, 2025
Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer.

Eric S Christenson, Won Jin Ho, Daniel Shu

|Jul 30, 2024
High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial.

Channing J Paller, Marianna L Zahurak, Adel Mandl

|Feb 07, 2024
Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells.

Junke Wang, Jessica Gai, Tengyi Zhang

Pageof 3

Frequent Collaborators

9 joint publications

Elizabeth M Jaffee

8 joint publications

Katherine M Bever

8 joint publications

Daniel Laheru

6 joint publications

Dung T Le